Research

My major research interest is investigating the alterations in metabolism that accompany B-cell activation and how this is reflected in the metabolism of low- and high grade lymphomas including chronic lymphocytic leukaemia/small lymphocytic lymphoma, diffuse large B cell lymphoma and Burkitt lymphoma. We use a variety of proteomic and metabolomic techniques to study these questions in primary patient samples, B-cell lines and murine conditional knockout and transgenic lymphoma models.  We are particularly interested in the impact of genetic aberrations of MYC and p53 on the metabolism of lymphoma cells and how this relates to high grade transformation of CLL (Richter syndrome). Our overall aim is that an enhanced understanding of the metabolism of normal and malignant B cells will underpin the development of the next generation of anti-metabolic drugs for these cancers and may also be of benefit in the treatment of non-malignant autoimmune conditions. In addition I am involved in teaching undergraduate and MSc students and am the course director for the MSc Cancer & Clinical Oncology Programme.

I combine my laboratory and translational research programme with clinical practice with the Cancer Centre at Barts Health, with specific emphasis on the treatment of lymphoid malignancies including CLL and lymphoma. In addition to my research in metabolism, I have a particular interest in the role of targeted therapies, immunotherapy and bone marrow transplantation in the treatment of these diseases.

External collaborators

Karen Vousden, The Francis Crick Institute, London, UK

Dinis Calado, The Francis Crick Institute, London, UK

James MacRae, The Francis Crick Institute, London, UK

Louisa James, The Blizzard Institute, QMUL, London, UK

Thomas Kipps, Moores Cancer Center, University of California, San Diego, USA

Laura Rassenti, Moores Cancer Center, University of California, San Diego, USA

Other Activities

• 2020 - present: Member of NCRI Lymphoma Subgroup
• 2019 - present: Member of UK CLL Forum Executive Committee
• 2019-present: Member of Pan-London Haemato-oncology guidelines writing group
• 2018-present: Course Director for the MSc Cancer & Clinical Oncology Programme
• 2015-present: Fellow of the Royal College of Pathologists
• 2012-present: Member of European Hematology Association
• 2014-2015: Intercollegiate Committee on Haematology
• 2014-2015: Trainees Advisory Committee Representative
• 2013-2015: UK CLL Forum Executive Committee

Major Funding

• 2020 - Wellcome Trust, Targeting phosphoglycerate dehydrogenase and serine biosynthesis in B-cell malignancies, £189,728
• 2020 - Barts Charity, Investigation of the potential of breath biopsy in haematological malignancies, £29,838
• 2019 - Kay Kendall Leukaemia Fund: Investigating the molecular mechanisms underlying increased glycolysis in high grade transformation of chronic lymphocytic leukaemia, £217,498
• 2019 - Greg Wolf Leukaemia Fund: Investigating the impact of TP53 abnormalities on glycolysis in Richter syndrome, £22,000
• 2016- Wellcome Trust Intermediate Clinical Fellowship, Understanding the impact of p53 abnormalities on cellular metabolism in chronic lymphocytic leukaemia, £863,503
• 2009 - Cancer Research UK Clinical Research Fellowship £206,000 over 3 years

Recent Publications

Impact of COVID-19 in patients with lymphoid malignancies. Riches JC World J Virol (2021) 10(2) 97-110
https://www.ncbi.nlm.nih.gov/pubmed/34079692

Single-cell analysis of human B cell maturation predicts how antibody class switching shapes selection dynamics King HW, Orban N, Riches JC et al. Science immunology (2021) 6(7)

Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper Eyre TA, Riches JC, Patten PEM et al. British Journal of Haematology (2021) (7)

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients Vijenthira A, Gong IY, Fox TA et al. Blood (2020) 136(7) 2881-2892

Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients. Aries JA, Davies JK, Auer RL et al. British Journal of Haematology (2020) (1)
https://www.ncbi.nlm.nih.gov/pubmed/32420609

B-Cell Receptor Signaling Drives Glycolysis in Chronic Lymphocytic Leukemia Cells Clear AJ, D'Avola A, Agrawal SG et al. Blood (2018) 132(10) 3121-3121

Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia. Riches JC, Gribben JG Current Cancer Drug Targets (2016) 16(1)
http://www.ncbi.nlm.nih.gov/pubmed/27055579

Mechanisms of PD-L1/PD-1 mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eμ-TCL1 CLL mouse model McClanahan F, Riches JC, Miller S et al. Blood (2015) 126(7) 212-221

PD-1/PD-L1 mediated T-cell dysfunction in CLL is not absolute and can be at least partially reversed in vivo by the immune-modulatory drug lenalidomide McClanahan F, Riches JC, Miller S et al. ONCOLOGY RESEARCH AND TREATMENT (2014) 37(11) 236-236
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343816900576&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a

Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations Riches JC, O'Donovan CJ, Kingdon SJ et al. Blood (2014) 123(7) 4101-4110

Team

Postdoctoral Researchers
Dr Katarina Kluckova, Dr Annalisa D’Avola (based at the Francis Crick Institute)

Postdoctoral Clinical Research Fellows
Lotte Stiekema 

PhD Students
Nicola Joseph

Biography

I undertook my undergraduate degree in medical sciences at the University of Cambridge before qualifying from Oxford University Medical School in 2003. I subsequently trained in haematology on the Imperial College training rotation based at Hammersmith hospital.

I developed my research interest during my CRUK Clinical Research Fellowship with Professor Gribben at Barts Cancer Institute where I studied the defects underlying impaired T-cell immunity in chronic lymphocytic leukaemia (CLL) focusing on the impact of lenalidomide, being awarded a PhD in 2013. I stayed in this laboratory for a period of post-doctoral work investigating the expression and function of integrins on CLL cells. I was awarded the Hamblin prize by the UK CLL forum in 2015 for my work documenting the particular differences associated with the presence of trisomy 12.

In 2016, I joined the Centre for Haemato-Oncology in the Barts Cancer Institute as a Clinical Senior Lecturer funded initially as an Intermediate Clinical Fellow by the Wellcome Trust. I have been working at the Francis Crick Institute to investigate the metabolism of normal and malignant B cells in collaboration with Professor Karen Vousden and Dinis Calado.

2018: Fellowship of the Higher Education Academy (FHEA)

2015: Fellowship of the Royal College of Pathologists (FRCPath)

2013: PhD, Queen Mary University of London

2006: Membership of the Royal College of Physicians (MRCP)

2003: MB BCh, University of Oxford

2000: MA Medical Sciences, University of Cambridge